Tranexamic Acid plus standard of care
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Femoral Fractures
Conditions
Femoral Fractures
Trial Timeline
Apr 1, 2009 → Jun 1, 2010
NCT ID
NCT00824564About Tranexamic Acid plus standard of care
Tranexamic Acid plus standard of care is a approved stage product being developed by Pfizer for Femoral Fractures. The current trial status is completed. This product is registered under clinical trial identifier NCT00824564. Target conditions include Femoral Fractures.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00824564 | Approved | Completed |
Competing Products
3 competing products in Femoral Fractures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 77 |
| zoledronic acid (aclasta) | Novartis | Phase 3 | 77 |
| Tissucol® | Baxter | Pre-clinical | 20 |